Merck - 52 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1970 adjusted for splits. The latest closing stock price for Merck as of September 07, 2022 is 86.87.
  • The all-time high Merck stock closing price was 94.96 on July 15, 2022.
  • The Merck 52-week high stock price is 95.72, which is 10.2% above the current share price.
  • The Merck 52-week low stock price is 70.89, which is 18.4% below the current share price.
  • The average Merck stock price for the last 52 weeks is 83.27.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 84.8889 75.5769 94.9600 72.2735 86.8700 15.29%
2021 74.6174 76.8186 88.1915 68.4783 75.3508 -2.92%
2020 75.3816 84.6524 84.6524 61.5558 77.6157 -7.21%
2019 74.4969 67.6843 84.3765 65.2935 83.6499 22.26%
2018 56.5395 48.8285 70.5348 46.6398 68.4185 40.00%
2017 53.1011 50.6817 56.9733 46.5879 48.8719 -1.47%
2016 47.6277 42.8364 54.3214 39.6612 49.6032 15.05%
2015 45.3220 45.1668 49.7791 39.1769 43.1140 -3.87%
2014 44.4299 37.9220 48.5030 37.9220 44.8509 16.95%
2013 34.8492 30.5402 38.3511 30.1783 38.3511 26.80%
2012 29.8300 27.1609 35.0875 26.4588 30.2447 13.13%
2011 23.5850 24.4073 26.8772 20.6422 26.7354 9.54%
2010 23.8309 24.0333 26.6438 20.8760 24.4073 2.86%
2009 18.7342 19.0930 24.6762 13.1398 23.7281 26.73%
2008 22.2131 33.8196 35.6942 14.3052 18.7234 -45.34%
2007 29.4224 25.1797 35.8239 24.5619 34.2558 37.36%
2006 21.4815 17.9988 26.2094 17.9988 24.9395 42.66%
2005 16.3875 16.3437 18.4821 14.0254 17.4822 4.04%
2004 21.4537 23.6905 24.7363 13.4098 16.8038 -27.76%
2003 25.4439 27.0010 29.7044 20.2709 23.2625 -11.35%
2002 24.6942 27.0084 29.2543 17.8601 26.2408 -1.26%
2001 31.7222 41.1084 41.1084 25.8378 26.5745 -35.79%
2000 32.3195 29.3822 41.8820 23.5478 41.3869 41.78%
1999 31.5490 32.0414 37.0796 26.2650 29.1911 -7.48%
1998 27.3293 22.6616 33.9451 21.6717 31.5495 41.32%
1997 19.7017 16.5166 22.5984 16.5166 22.3246 35.61%
1996 13.9083 13.0055 17.3327 11.5953 16.4628 23.92%
1995 9.8939 7.5733 13.5379 7.2023 13.2849 76.57%
1994 6.4497 6.7187 7.7706 5.4566 7.5239 14.82%
1993 6.5813 8.1180 8.1180 5.3890 6.5529 -18.35%
1992 8.8843 10.0612 10.2117 7.5678 8.0255 -20.29%
1991 7.1823 5.3080 10.0684 4.8780 10.0684 88.88%
1990 4.6245 4.5468 5.3305 3.9065 5.3305 18.95%
1989 4.0252 3.2317 4.5995 3.2317 4.4814 37.47%
1988 3.0483 3.0171 3.3365 2.6707 3.2600 12.05%
1987 3.0857 2.3128 3.9923 2.3128 2.9093 27.95%
1986 1.7549 1.2665 2.3770 1.2425 2.2737 80.84%
1985 1.0078 0.8547 1.2573 0.8295 1.2573 45.74%
1984 0.8133 0.8295 0.8902 0.7319 0.8627 4.00%
1983 0.8347 0.7709 0.9568 0.7526 0.8295 6.81%
1982 0.7056 0.7847 0.8053 0.5897 0.7766 -0.15%
1981 0.7977 0.7893 0.9396 0.7021 0.7778 0.00%
1980 0.6676 0.6493 0.7778 0.5392 0.7778 17.30%
1979 0.6197 0.6230 0.6780 0.5747 0.6631 6.85%
1978 0.5285 0.4921 0.6345 0.4417 0.6206 21.83%
1977 0.5154 0.6149 0.6149 0.4624 0.5094 -18.52%
1976 0.6564 0.6390 0.7377 0.5782 0.6252 -1.64%
1975 0.6835 0.6172 0.7847 0.5392 0.6356 4.33%
1974 0.6596 0.7377 0.7858 0.4497 0.6092 -17.80%
1973 0.8198 0.8306 0.9224 0.7136 0.7411 -9.39%
1972 0.7010 0.5748 0.8214 0.5748 0.8179 43.74%
1971 0.4864 0.4359 0.6000 0.4359 0.5690 25.25%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $218.926B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $429.030B 16.33
Eli Lilly (LLY) United States $291.533B 36.97
Pfizer (PFE) United States $256.821B 7.53
AbbVie (ABBV) United States $243.272B 10.34
Novo Nordisk (NVO) Denmark $234.421B 30.92
Novartis AG (NVS) Switzerland $176.499B 13.01